Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Hepion Pharmaceuticals ( (HEPA) ) has provided an update.
On April 30, 2025, Hepion Pharmaceuticals entered into a binding letter of intent with New Day Diagnostics to in-license diagnostic tests for diseases including celiac disease, respiratory multiplex, H. pylori, and hepatocellular carcinoma. The agreement involves an initial payment of $525,000 in cash and $200,000 in common stock, with potential additional payments up to $17.15 million based on milestones, and royalties on net sales. This strategic move could enhance Hepion’s product offerings and market presence in Europe, where some tests are already eligible for sale.
More about Hepion Pharmaceuticals
Hepion Pharmaceuticals is a company involved in the pharmaceutical industry, focusing on developing treatments and diagnostic tests for various diseases.
Average Trading Volume: 4,451,849
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.11M
Find detailed analytics on HEPA stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue